Loading
NASDAQHealthcareBiotechnology
Latest quote
$13.74
−$1.44 · -9.49%
Eloxx Pharmaceuticals is a clinical-stage biopharmaceutical firm that specializes in developing therapeutic solutions through ribosome modulation. Its primary objective is to address rare and ultra-rare genetic diseases that arise from premature stop codons. The company's most advanced investigational compound, ELX-02, is currently progressing through Phase 2 clinical trials. This candidate is being evaluated for its potential to treat patients with cystic fibrosis and nephropathic cystinosis who possess diagnosed nonsense mutations. In addition to its lead program, Eloxx is actively pursuing several preclinical projects aimed at conditions like Alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis. The company also maintains various earlier-stage discovery initiatives focused on oncology. Eloxx Pharmaceuticals was established in 2013 and is headquartered in Watertown, Massachusetts.
Latest quote
$13.74
−$1.44 · -9.49%
After-hours
$13.74
$0.00 · 0.00%
Oct 9, 4:10 PM ET
Regular session · ET · Market data may be delayed.
Eloxx Pharmaceuticals is a clinical-stage biopharmaceutical firm that specializes in developing therapeutic solutions through ribosome modulation. Its primary objective is to address rare and ultra-rare genetic diseases that arise from premature stop codons. The company's most advanced investigational compound, ELX-02, is currently progressing through Phase 2 clinical trials. This candidate is being evaluated for its potential to treat patients with cystic fibrosis and nephropathic cystinosis who possess diagnosed nonsense mutations. In addition to its lead program, Eloxx is actively pursuing several preclinical projects aimed at conditions like Alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis. The company also maintains various earlier-stage discovery initiatives focused on oncology. Eloxx Pharmaceuticals was established in 2013 and is headquartered in Watertown, Massachusetts.
Day range
Current $13.74
52-week range
Current $13.74
Regular session · ET · Market data may be delayed.
Eloxx Pharmaceuticals is a clinical-stage biopharmaceutical firm that specializes in developing therapeutic solutions through ribosome modulation. Its primary objective is to address rare and ultra-rare genetic diseases that arise from premature stop codons. The company's most advanced investigational compound, ELX-02, is currently progressing through Phase 2 clinical trials. This candidate is being evaluated for its potential to treat patients with cystic fibrosis and nephropathic cystinosis who possess diagnosed nonsense mutations. In addition to its lead program, Eloxx is actively pursuing several preclinical projects aimed at conditions like Alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis. The company also maintains various earlier-stage discovery initiatives focused on oncology. Eloxx Pharmaceuticals was established in 2013 and is headquartered in Watertown, Massachusetts.
Day range
Current $13.74
52-week range
Current $13.74
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | 6.36M USD | — | — | — |
| Cost of goods sold | — | — | — | 695K USD | 960K USD |
| Gross profit | — | 6.36M USD | — | −695K USD | −960K USD |
| Research and development | 3.06M USD | 3.58M USD | 8.6M USD | 23.73M USD | 22.9M USD |
| Selling, general, and administrative | 3.38M USD | 5.25M USD | 8.69M USD | 10M USD | 18.49M USD |
| Operating expenses | 6.44M USD | 8.83M USD | 17.29M USD | 33.72M USD | 41.39M USD |
| Interest income | 33K USD | 27K USD | 252K USD | 274K USD | 8K USD |
| Interest expense | 1.05M USD | 1.14M USD | 1.15M USD | 1.95M USD | 1.26M USD |
| Depreciation and amortization | — | 164K USD | 809K USD | 695K USD | 960K USD |
| Operating income | −6.44M USD | −2.47M USD | −17.29M USD | −34.42M USD | −42.35M USD |
| Net income | −6M USD | −3.14M USD | −17.05M USD | −36.07M USD | −66.73M USD |
Company facts updated Oct 9, 2026.
Third-party consensus; not a GoAI recommendation.
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Jun 1, 2026 | 1:11 | — | — |
Stock split | Dec 2, 2022 | 1:40 | — | — |
Stock split | Dec 20, 2017 | 1:20 | — | — |
Stock split | Oct 21, 2013 | 1:100 | — | — |
Stock split | Oct 25, 1999 | 2:1 | — | — |
Effective Jun 1, 2026
1:11
Effective Dec 2, 2022
1:40
Effective Dec 20, 2017
1:20
Effective Oct 21, 2013
1:100
Effective Oct 25, 1999
2:1
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
